دورية أكاديمية
أعرض في EDS

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.

التفاصيل البيبلوغرافية
العنوان: Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
المؤلفون: Amjed S; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan. amjedsameen@gmail.com.; Medical Laboratory Technology Department, Faculty of Rehabilitation and Allied Health Sciences, RIPHAH International University, Gulberg Campus, Lahore, Pakistan. amjedsameen@gmail.com., Saleem HGM; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.; Medical Laboratory Technology Department, Faculty of Rehabilitation and Allied Health Sciences, RIPHAH International University, Gulberg Campus, Lahore, Pakistan., Ullah S; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan., Latif S; Gastroenterology Department, Akthar Saeed Medical and Dental College, Lahore, Pakistan., Shabana; Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan., Jafar J; Specilized Health Care and Medical Education Department, Lahore, Punjab, Pakistan., Waqar AB; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.
المصدر: BMC infectious diseases [BMC Infect Dis] 2024 Mar 11; Vol. 24 (1), pp. 301. Date of Electronic Publication: 2024 Mar 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Hepatitis C, Chronic*/drug therapy , Hepatitis C, Chronic*/genetics , Anemia*/chemically induced , Anemia*/genetics , Hepatitis C*/drug therapy, Humans ; Ribavirin/adverse effects ; Sofosbuvir/adverse effects ; Antiviral Agents/adverse effects ; Inosine Triphosphatase ; Hepacivirus/genetics ; Prospective Studies ; Polymorphism, Single Nucleotide ; Pyrophosphatases/genetics ; Pyrophosphatases/therapeutic use ; Genotype ; Hemoglobins/genetics ; Treatment Outcome
مستخلص: Background: Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects. Polymorphisms of Inosine triphosphatase (ITPA) gene may cause functional impairment in the Inosine triphosphate pyrophosphatase enzyme, resulting in enhanced sustained viral response (SVR) and protection from ribavirin-associated anemia in patients on therapy. The study objective was to investigate the effect of Inosine triphosphatase gene polymorphism on SVR achievement, hemoglobin decline and ribavirin dose reduction in patients on therapy.
Methods: This prospective cohort study was of 170 hepatitis C infected patients received 6-month sofosbuvir ribavirin therapy. Patient viral load, reduction in ribavirin amount, liver function test, and complete blood count were noted monthly. Inosine triphosphatase variants rs1127354 and rs7270101 were assessed through the restriction fragment length polymorphism and confirmed using Sanger sequencing. The impact of polymorphism on cumulative reduction of ribavirin, and anti-HCV therapy outcome were studied.
Results: A total of 74.3% of patients had ITPA rs1127354 CC genotype, 25.7% were CA and AA 0%. The frequency of ITPA genotype rs7270101-AA was 95%, AC 5%, and CC was 0%. ITPA rs1127354-CA had a notably positive impact on SVR achievement with a zero-relapse rate. ITPA rs1127354-CA genotype was significantly (P ˂0.05) protective against ≥ 2 g/dl Hb reduction from baseline to 1st, 2nd and 6th months of therapy. During treatment, Hb reduction ≥ 10 g/dl was frequently observed in rs1127354-CC genotype and rs7270101-AA genotype patients. Ribavirin dose reduction was significantly (P ˂0.05) high in rs1127354-CC genotype as compared to genotype CA whereas no significant difference was observed in ribavirin dose reduction in rs7270101 AA and non-AA genotype. Patient baseline characteristics such as age, body mass index, rs1127354-CC genotype, and baseline Hb were significantly associated with significant Hb reduction.
Conclusion: Pretreatment evaluation of ITPA polymorphism can be a diagnostic tool to find out patients at risk of anemia and improve treatment adherence. ITPA genotype rs1127354-CA contributes to improved compliance with ribavirin dose and protects against hemoglobin decline in HCV patients while taking ribavirin-based therapy. However, ITPA rs1127354, rs7270101 polymorphism have no significant impact on SVR achievement.
(© 2024. The Author(s).)
References: Pharmacol Res Perspect. 2021 Aug;9(4):e00811. (PMID: 34152088)
J Gastroenterol. 2017 Jun;52(6):746-753. (PMID: 27822709)
Gut Liver. 2015 Mar;9(2):214-23. (PMID: 25287171)
J Hepatol. 2014 Jan;60(1):191-6. (PMID: 23973931)
J Clin Pharm Ther. 2020 Dec;45(6):1218-1227. (PMID: 32735044)
Hepatol Res. 2016 Nov;46(12):1256-1263. (PMID: 26916827)
Nature. 2010 Mar 18;464(7287):405-8. (PMID: 20173735)
Semin Liver Dis. 2011 Nov;31(4):375-86. (PMID: 22189977)
Pharmacogenomics. 2015;16(10):1179-88. (PMID: 26250055)
J Hepatol. 2013 Oct;59(4):667-74. (PMID: 23707372)
Clin Infect Dis. 2015 Sep 1;61(5):730-40. (PMID: 25987643)
J Med Virol. 2017 Oct;89(10):1823-1829. (PMID: 28480960)
J Viral Hepat. 2013 Dec;20(12):858-66. (PMID: 24304455)
Indian J Gastroenterol. 2016 Jan;35(1):7-13. (PMID: 26880169)
J Med Virol. 2011 Jun;83(6):1048-57. (PMID: 21503919)
J Pak Med Assoc. 2019 Nov;69(11):1637-1641. (PMID: 31740870)
Gastroenterology. 2010 Oct;139(4):1190-7. (PMID: 20637204)
Hepatol Res. 2019 Aug;49(8):853-859. (PMID: 31009550)
Viral Immunol. 2017 May;30(4):252-257. (PMID: 28118096)
J Clin Lab Anal. 2018 Sep;32(7):e22440. (PMID: 29660762)
J Med Virol. 2016 Oct;88(10):1776-84. (PMID: 26991414)
Hepatol Res. 2014 Oct;44(10):E84-91. (PMID: 23957840)
Viral Immunol. 2017 Apr;30(3):178-195. (PMID: 28085634)
J Korean Med Sci. 2013 Aug;28(8):1213-9. (PMID: 23960450)
PLoS One. 2015 Oct 06;10(10):e0139317. (PMID: 26441325)
Gastroenterology. 2019 Jan;156(2):400-417. (PMID: 30287169)
J Gastroenterol Hepatol. 2017 Aug;32(8):1495-1502. (PMID: 28109022)
Pharmacogenomics. 2016 Jun;17(8):925-41. (PMID: 27248282)
Nat Rev Dis Primers. 2017 Mar 02;3:17006. (PMID: 28252637)
Hepatology. 2011 Feb;53(2):389-95. (PMID: 21274861)
J Clin Virol. 2015 Jul;68:56-60. (PMID: 26071337)
فهرسة مساهمة: Keywords: Anemia; HCV; ITPA; Polymorphism; Ribavirin
المشرفين على المادة: 49717AWG6K (Ribavirin)
WJ6CA3ZU8B (Sofosbuvir)
0 (Antiviral Agents)
EC 3.6.1.- (Inosine Triphosphatase)
EC 3.6.1.- (Pyrophosphatases)
0 (Hemoglobins)
EC 3.6.1.9 (ITPA protein, human)
تواريخ الأحداث: Date Created: 20240312 Date Completed: 20240313 Latest Revision: 20240315
رمز التحديث: 20240315
مُعرف محوري في PubMed: PMC10926675
DOI: 10.1186/s12879-024-09188-1
PMID: 38468199
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا